Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.

By K. Garey, M. Rege, M. Pai, Dana E Mingo, K. Suda, R. Turpin, D. Bearden. Clinical Infectious Diseases, 2006

1,163 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/e1a67fd5e540307550577ea7a071370b075e943f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. M. Pfaller
2. D. Diekema
3. J. Guinea
4. D. Kontoyiannis
5. T. Walsh
6. Thierry Calandra
7. J. Perfect
8. E. Anaissie

In Infectious Diseases

1. M. Pfaller
2. D. Diekema
3. J. Guinea
4. D. Kontoyiannis
5. Georgios Chamilos
6. J. Fishman
7. J. Perfect
8. E. Anaissie

Citations in the corpus

• Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “mortality [14, 17, 18, 236].”
• Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. (2008, background): “Furthermore, 2 recent retrospective cohort studies demonstrated that the early initiation of effective empirical antifungal therapy within 12 h after the first finding of a blood sample positive for Candida infection is critical for a successful outcome among patients with candidemia [15, 16].”
• Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America (2009, background): “Early initiation of effective antifungal therapy is critical in the successful treatment of candidemia, as demonstrated by recent data suggesting higher mortality rates among patients with candidemia whose therapy was delayed [77, 78].”
• Resistance to Antifungal Agents: Mechanisms and Clinical Impact (2008, background): “Third, recent data support that early treatment of fungal infection with a lower burden of organisms reduces the number of treatment failures [103-105].”
• Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. (2009, background): “Inappropriate therapy or delays in initiation of therapy have also been linked to increased mortality [24, 25].”
• Global trends in the distribution of Candida species causing candidemia. (2014, background): “The mortality rate is clearly correlated with a delay in the initiation of appropriate antifungal treatment [14,15].”
• Epidemiology of Invasive Mycoses in North America (2010, background): “…treatment with an agent to which the organism is resistant, inadequate dose or duration of treatment, or no treatment at all (Armstrong-James 2007; Atkinson et al. 2008; Garey et al. 2006; Garey et al. 2007; Klevay et al. 2008; Morgan et al. 2005a; Morrell et al. 2005; Parkins et al. 2007).”